UniPat AI Launches EchoZ Prediction Model, Demonstrating Performance Beyond Human Traders on Polymarket
BEIJING, April 10, 2026 (GLOBE NEWSWIRE) -- UniPat AI announces benchmark…
Trogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model
A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in…
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
March 27, 2026 10:30 ET | Source: Celldex Therapeutics, Inc. - Improvements…
MEXC Ranks No. 1 in XAUT Perpetual Volume Globally, Demonstrating Strong Liquidity and User Activity
VICTORIA, Seychelles, March 4, 2026 /PRNewswire/ -- MEXC, the world's fastest-growing digital asset…
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
March 01, 2026 09:45 ET | Source: Celldex Therapeutics, Inc. - Late…
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) today…
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
• Patient 1 of Cohort 1 has now completed the 24-month follow-up…
Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinsons Disease
December 05, 2025 21:00 ET | Source: Cerevance, Inc. Phase 2 results…
ADNOC Gas Delivers Best-Ever Q3 Results, Demonstrating Resilience and Growth in a Dynamic Market
Record Q3 net income of $1.34 billion, up 8% year-on-year Year-to-date net…
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.…
